Why is comorbidity the norm, not the exception, in ADHD?
Comorbidity is now recognised as the rule, not the exception, among adults with ADHD. Most individuals experience at least one additional psychiatric or medical condition. According to the 2025 NHS ADHD Taskforce report and NICE guidance (NG87), overlapping symptoms, shared neurobiological mechanisms, and psychosocial stress factors all contribute to the high comorbidity rates seen in adult ADHD. This complexity often makes accurate diagnosis and treatment more challenging, as noted by the Royal College of Psychiatrists (RCPsych).
Prevalence and types of comorbidities
Recent NHS and NICE data estimate that between 60% and 80% of adults with ADHD live with at least one other psychiatric or physical health condition. The most common comorbidities include anxiety disorders such as generalised anxiety and panic disorder, which affect around half of adults with ADHD. Depressive disorders occur in up to 50% of cases, while bipolar disorder affects roughly 7–17%. The overlap with autism spectrum disorder is also well documented and now explicitly recognised in NICE guidance. Substance use, sleep disturbance, eating difficulties, and chronic pain are also significantly more common than in the general population according to NHS data.
Why comorbidity is so common: neurobiology and psychosocial explanations
A 2025 meta-analysis in PubMed and RCPsych guidance report that ADHD shares genetic and neurobiological pathways with anxiety, depression, and autism. These include alterations in dopamine and noradrenaline circuits, which influence mood, motivation, and focus. Neuroimaging studies have identified overlapping areas of cortical thinning and disrupted attention networks across these conditions. Psychosocial stressors, including chronic underachievement, work stress, and relationship strain, also increase the risk of developing secondary mental health problems. When ADHD remains untreated, long-term emotional distress often leads to anxiety and depression.
Diagnostic and clinical implications
Both NICE and RCPsych highlight that symptom overlap contributes to frequent misdiagnosis or diagnostic delay. For example, inattentive ADHD can be mistaken for depression, while mood instability may be misattributed to bipolar disorder. UK ADHD services are often split between neurodevelopmental and general mental health pathways, making it difficult for clinicians to assess complex presentations. NICE therefore recommends multidisciplinary assessment, involving structured interviews, collateral history, and evaluation across different life settings to capture the full picture.
Evidence-based management strategies
Effective management must address ADHD and its comorbidities together. NICE guidance and NHS England both recommend integrated care pathways that combine medication, psychological support such as CBT, and lifestyle strategies. Treating coexisting conditions simultaneously improves overall functioning and reduces relapse risk, as highlighted in a 2024 Lancet Psychiatry review. Specialist “complex case” clinics and neurodivergent adult pathways are also being piloted in the UK to improve outcomes for adults with multiple diagnoses.
Key takeaway
According to NICE, NHS England, and the Royal College of Psychiatrists, high comorbidity in ADHD stems from shared neurobiological vulnerabilities and life stress factors that amplify one another over time. Recognising ADHD as a condition that rarely exists in isolation allows for earlier detection, more accurate diagnosis, and better integrated care. Comorbidity may be the norm, but with coordinated treatment and long-term support, adults can experience meaningful improvements in stability, wellbeing, and daily function.

